Peptide·plain sequence-like

ATLPC0031703

DRVYIHPFHL

Compare in workbench Download release API JSON

Length
10 aa
Monoisotopic mass
1295.7 Da
Net charge @ pH 7.4
0.20
Isoelectric point
7.71
GRAVY
-0.200

Coveragecounts only · not riskATLPC0031703

Measurements
13
Endpoints
3
Domains
3/5
Products
—

11 stability measurements
1 clearance measurement
No immunogenicity context
No sequence liability cues

Jump to domain

Open the matching evidence section below

All evidence index · 13

Exposure / Absorption

No evidence

Distribution / Barrier

1 measurement

Metabolic & Proteolytic Stability

11 measurements

Excretion / Persistence

1 measurement

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 10
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0034438	—	—	—	Notation only	12

Residue view

Residue display

10 residues

D1R2V3Y4I5H6P7F8H9L10

Secondary structureα-helix (H)β-strand (E)coil (C)

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

DRVYIHPFHL

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references1 reference

3D coordinates·Exact PDB matchexperimental

Exact PDB match·reference selected·length 10 aa·confidence experimental

Link	Method	Confidence	Match
Open	Experimental coordinate entry	experimental	10 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors10 aa · pI 7.7 · GRAVY -0.20

Length: 10 aa
Monoisotopic mass: 1295.68 Da
Average mass: 1296.49 Da
Net charge at pH 7.4: 0.20
Estimated pI: 7.71
GRAVY: -0.200
KD-positive residues: 40.0%
Aromatic residues: 20.0%

Developability interpretation

Ionization context: pH 7.4 close to pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.70
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

3.96

pH 5

2.05

pH 6

1.53

pH 7.4

0.16

pH 9

-0.78

pH 12

-2.23

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

1 · 10.0%

Basic (K,R,H)

3 · 30.0%

Hydrophobic aliphatic (A,V,I,L,M)

3 · 30.0%

Aromatic (F,W,Y)

2 · 20.0%

Conformational / sulfur (G,P,C)

1 · 10.0%

Top residues

H220.0%R110.0%D110.0%I110.0%L110.0%F110.0%P110.0%Y110.0%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

3-9

VYIHPFH

GRAVY 0.314

Most hydrophilic window

1-7

DRVYIHP

GRAVY -0.771

4 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

No conservative sequence-liability motifs from the current rule set are present.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.70100°/residue · 10 aa

Hydrophobic moment0.70

Mean K-D hydropathy-0.20

Approx. net charge0

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

107.00

Instability index

22.6

At or below 40 — predicted stable in vitro.

Boman index

1.62 kcal/mol

Molar extinction coefficient (280 nm)

1,490 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 1.15

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Distribution / Barrier

1 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBBB penetration

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

BBB penetration1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation source reported BBB observation	Interpret as reported	Not specified	Result: Qualitative or narrative result · Molecular form: not reported · Source: Primary reference linked	Source record

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Metabolic & Proteolytic Stability

11 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability11 records · 11 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	1.9 hours 6840 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%)	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
2	8.7 hours 31319.999999999996 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%) + Heat inactivation	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
3	9.2 hours 33120 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%)	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
4	44.6 hours 160560 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%) + converting enzyme inhibitor (MK422) with conc 10-6 M	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
5	0.6 hours 2160 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%)	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
6	1.2 hours 4320 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%) + converting enzyme inhibitor (MK422) with conc 10-6 M	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
7	4 hours 14400 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%)	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
8	8.3 hours 29880.000000000004 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%) + converting enzyme inhibitor (MK422) with conc 10-6 M	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
9	12.6 hours 45360 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%) + heat inactvation	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference
10	4 hours 14400 seconds	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10-6 M	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked	Reference

1–10 / 11

Excretion / Persistence

1 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	1 hours 3600 seconds	Eligible when experimental context matches	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro · Source: Primary reference linked	Reference

Evidence landscape

13 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

1 evidence record

Metabolic & Proteolytic Stability

11 evidence records

Excretion / Persistence

1 evidence record

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Serum Plasma Stability

Blood Brain Barrier Penetration

Half Life

Assay context

Broad context buckets, useful before comparing values.

Matrix / stability

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReference

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	9.2 hours 33,120 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%)	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
2	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	12.6 hours 45,360 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%) + heat inactvation	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
3	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	1.2 hours 4,320 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%) + converting enzyme inhibitor (MK422) with conc 1...	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
4	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	8.7 hours 31,320 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%) + Heat inactivation	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
5	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	44.6 hours 160,560 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%) + converting enzyme inhibitor (MK422) with conc...	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
6	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	4 hours 14,400 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%)	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	9.9 hours 35,640 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10...	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
8	Excretion / Persistence Persistence	Half Life	1 hours 3,600 seconds	Reported point value	Eligible when experimental context matches	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Time: Room Temperature · Dose/window: 1mg/mL · Protease: Hydolytic activity of bacterial strain B-9 · in vitro	Reference Primary reference linked
9	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	0.6 hours 2,160 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%)	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked
10	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	1.9 hours 6,840 seconds	Reported point value	Eligible when experimental context matches	Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%)	Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro	Reference Primary reference linked

1–10 / 13

Identity & reference map

13 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary3 reference groups

Identity type: canonical sequence
Reported notation: 0
Reference groups: 3
Measurements: 13
ATL peptide ID: ATLPC0031703

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 13

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 13

Different notation

Reported notation does not resolve to the current display sequence.

0 / 13

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

13 / 13

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

DRVYIHPFHL

Reported names

No distinct human-readable aliases are exposed.

Reference map3 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Stability Serum Plasma Stability	No reported alias	11 identity 11 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Source record Open	Distribution Blood Brain Barrier Penetration	No reported alias	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0031703
Identity type: canonical sequence
ADMET endpoints: 3
Evidence records: 13
Reference groups: 3
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0031703

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0031703' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0034438

—

Notation only

Link

Method

Confidence

Match

Open

Experimental coordinate entry

experimental

10 aa

Value

Analysis use

Assay / model

Result context

Reference

Observation

source reported BBB observation

Interpret as reported

Not specified

Result: Qualitative or narrative result · Molecular form: not reported · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

1.9 hours

6840 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%)

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

8.7 hours

31319.999999999996 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%) + Heat inactivation

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

9.2 hours

33120 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%)

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

44.6 hours

160560 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%) + converting enzyme inhibitor (MK422) with conc 10-6 M

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

0.6 hours

2160 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%)

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

1.2 hours

4320 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%) + converting enzyme inhibitor (MK422) with conc 10-6 M

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

4 hours

14400 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%)

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

8.3 hours

29880.000000000004 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%) + converting enzyme inhibitor (MK422) with conc 10-6 M

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

12.6 hours

45360 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%) + heat inactvation

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

4 hours

14400 seconds

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10-6 M

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 100 - 2000 ng/ml · Fetal calf serum proteases · in vitro · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

1 hours

3600 seconds

Eligible when experimental context matches

HPLC and LC/ITMS · Bacterial strain B-9 cell culture

Result: Reported point value · Molecular form: ATLPF0034438 · Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro · Source: Primary reference linked

Reference

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

9.2 hours

33,120 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%)

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

12.6 hours

45,360 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%) + heat inactvation

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

1.2 hours

4,320 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%) + converting enzyme inhibitor (MK422) with conc 1...

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

8.7 hours

31,320 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%) + Heat inactivation

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

44.6 hours

160,560 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (2.5%) + converting enzyme inhibitor (MK422) with conc...

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

4 hours

14,400 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (5%)

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

9.9 hours

35,640 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum(10%) + converting enzyme inhibitor (MK422) with conc 10...

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

1 hours

3,600 seconds

Reported point value

Eligible when experimental context matches

HPLC and LC/ITMS · Bacterial strain B-9 cell culture

Time: Room Temperature · Dose/window: 1mg/mL · Protease: Hydolytic activity of bacterial strain B-9 · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

0.6 hours

2,160 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (20%)

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

1.9 hours

6,840 seconds

Reported point value

Eligible when experimental context matches

Radioimmunoassay · Primary endothelial cells + Fetal calf Serum (10%)

Dose/window: 100 - 2000 ng/ml · Protease: Fetal calf serum proteases · in vitro

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

Stability

Serum Plasma Stability

No reported alias

11 identity

11 evidence

Reference

Open

Persistence

Half Life

No reported alias

1 identity

1 evidence

Source record

Open

Distribution

Blood Brain Barrier Penetration

No reported alias

1 identity

1 evidence

ATLPC0031703

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Distribution / Barrier

Metabolic & Proteolytic Stability

Excretion / Persistence

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue

ATLPC0031703

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Distribution / Barrier

Metabolic & Proteolytic Stability

Excretion / Persistence

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue